Researchers from Exscientia plc presented preclinical data for the novel reversible LSD1 inhibitor EXS-74539, being developed as a monotherapy or in combination with standard of care for the treatment of oncology and hematology indications including acute myeloid leukemia (AML) and small-cell lung cancer.
Seed Therapeutics Inc., a subsidiary of Beyondspring Inc., has reported the discovery of ST-00937, a new chemical entity molecular glue with IND candidate status that will be advanced for the treatment of cancers.
Inhibitors of diacylglycerol kinase, particularly diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ), believed to be useful for the treatment of cancer and viral infections, have been disclosed by Inventisbio Co. Ltd. and Inventisbio LLC.
An Oncolinea Pharmaceuticals Inc. patent describes nucleosides acting as DNA repair inhibitors and thus reported to be useful for the treatment of cancer.
Gliomas are the most common brain tumors. Adult gliomas frequently present molecular alterations in the epidermal growth factor receptor (EGFR) and its associated signaling pathways. In recent work, researchers from the Centre de Biophysique Moléculaire (France) and collaborators demonstrated the role of the serotonin 5-HT7 receptor (5-HT7R) in a larval Drosophila model of glioma, showing that it may act as a tumor suppressor.
Researchers from Boehringer Ingelheim Pharma GmbH & Co. KG presented the discovery and preclinical characterization of BI-3706674, a potent and orally available small-molecule inhibitor of the KRAS oncogene, targeting both KRAS-mutant and KRAS wild-type amplified (WTamp) cancers.
Can-Fite Biopharma Ltd. has entered into an agreement with Collaborations Pharmaceuticals Inc. (CPI) to develop anticancer drugs utilizing artificial intelligence (AI) and machine learning (ML) techniques.
Heat shock protein 90 (Hsp90) consists of four isoforms. Among them, the Hsp90α is overexpressed in advanced tumors and involved in tissue repair, tumor migration and metastasis as well. Researchers from Fujian Medical University (FJMU) reported on the discovery and preclinical characterization of [I], a selective proteolysis targeting chimera (PROTAC) acting as an Hsp90α protein degradation inducer for breast cancer treatment.
Peel Therapeutics believes evolutionary biology holds the key to developing new therapeutics for cancer and inflammation, a relatively unique approach in the world of biotech, but one that is bearing fruit: Its lead molecule is derived from camptothecin, a compound originating from the Chinese Happy Tree that is thought to have evolved as a plant defense mechanism, and it has progressed to a phase I dose escalation study in patients with advanced solid tumors.
RSS
